Logo

American Heart Association

  9
  0


Final ID: Sa3109

Clinical characteristics and treatment of high-risk cardiovascular patients without prior myocardial infarction or stroke: VESALIUS-REAL - results from US

Abstract Body (Do not enter title and authors here): Background: Early intervention with lipid lowering therapy (LLT) in patients with high cardiovascular (CV) risk before myocardial infarction or stroke may have substantial public health benefits, despite being perceived as less urgent. The effect of evolocumab in this population is being investigated in an ongoing clinical trial (NCT03872401: Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke [VESALIUS-CV]). The current ongoing observational study examines the global burden of a VESALIUS-CV-like population in the REAL-world (“VESALIUS-REAL") in eight regions. We present data here on baseline characteristics and LLT of VESALIUS-CV like patients in the US.

Methods: Using the eligibility criteria aligned with VESALIUS-CV (Figure), data were extracted from HealthVerity medical and pharmacy claims (2016-2023). A two-year observability period was required before index date; therefore, the first possible cohort entry was on January 1, 2018.

Results: There were 518,852 VESALIUS-CV like patients with median age of 72 years (Q1-Q3: 64-79 years) and 56% were female (Table). Overall, 43% had coronary artery disease and 34% had high-risk diabetes mellitus (DM). Median low density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol and apolipoprotein B were 114 (Q1-Q3: 97-138) mg/dL, 141 (122-168) mg/dL and 92 (181-110) mg/dL, respectively. About 22% were on background LLT of whom 87% were on statins alone. Patients on LLT vs. no LLT were younger (median age 65 [Q1-Q3: 59-72] vs. 73 [66-80] years), had higher prevalence of tobacco users (29% vs. 17%) and high-risk DM (45% vs. 31%).

Conclusions: In a large cohort of VESALIUS-CV like US patients, the majority had LDL-C sub-optimally managed with most not taking any LLT. This finding suggests an opportunity to reduce the treatment gap and improve lipid management in this population.
  • Chan, Queenie  ( Amgen Ltd , London , United Kingdom )
  • Jernberg, Tomas  ( Karolinska Institute , Stockholm , Sweden )
  • Cegla, Jaimini  ( Imperial College London , London , United Kingdom )
  • Budoff, Matthew  ( LUNDQUIST INSTITUTE , Torrance , California , United States )
  • Wong, Ian  ( Hong Kong University , Hong Kong , Hong Kong )
  • Sakhuja, Swati  ( Amgen Inc , Thousand Oaks , California , United States )
  • Ochs, Andreas  ( Amgen Ltd , London , United Kingdom )
  • Dhalwani, Nafeesa  ( Amgen Inc , Thousand Oaks , California , United States )
  • O'kelly, James  ( Amgen Ltd , London , United Kingdom )
  • Shannon, Erin  ( Amgen Inc , Thousand Oaks , California , United States )
  • Paivadasilva Lima, Gabriel  ( Amgen Inc , Thousand Oaks , California , United States )
  • Avcil, Suna  ( Amgen Inc , Thousand Oaks , California , United States )
  • Laufs, Ulrich  ( University Clinic Leipzig , Leipzig , Germany )
  • Author Disclosures:
    Queenie Chan: DO have relevant financial relationships ; Employee:Amgen Ltd:Active (exists now) ; Individual Stocks/Stock Options:Amgen INC:Active (exists now) | Tomas Jernberg: No Answer | Jaimini Cegla: No Answer | Matthew Budoff: DO have relevant financial relationships ; Researcher:General Electric:Active (exists now) | Ian Wong: DO have relevant financial relationships ; Research Funding (PI or named investigator):Amgen:Active (exists now) ; Research Funding (PI or named investigator):GSK:Past (completed) | Swati Sakhuja: DO have relevant financial relationships ; Employee:Amgen Inc.:Active (exists now) | Andreas Ochs: DO have relevant financial relationships ; Employee:Amgen Ltd:Active (exists now) ; Individual Stocks/Stock Options:Amgen Inc:Active (exists now) | Nafeesa Dhalwani: No Answer | James O'Kelly: DO have relevant financial relationships ; Employee:Amgen:Active (exists now) ; Individual Stocks/Stock Options:Amgen:Active (exists now) | Erin Shannon: DO have relevant financial relationships ; Individual Stocks/Stock Options:Amgen, Inc.:Active (exists now) ; Employee:Amgen, Inc.:Active (exists now) | Gabriel PaivadaSilva Lima: DO have relevant financial relationships ; Employee:Amgen inc:Active (exists now) ; Individual Stocks/Stock Options:Amgen inc:Active (exists now) | Suna Avcil: No Answer | Ulrich Laufs: DO have relevant financial relationships ; Speaker:Amgen, Daiichi, Novartis, Sanofi:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Clinical Prediction, Prognosis, and Decision-Making

Saturday, 11/16/2024 , 02:00PM - 03:00PM

Abstract Poster Session

More abstracts on this topic:
Efficacy of Lipid-Lowering Therapies in Reducing Stroke Risk in Intracranial Atherosclerosis: A Systematic Review and Meta-Analysis

Abdelkader Omar, Shourav Md Manjurul Islam, Vallamchetla Sai Krishna, Elnaggar Ali, Ramadan Doaa, Badi Mohammed, Meschia James, Lin Michelle

A Randomized Placebo-Controlled Trial of Pitavastatin Calcium to Treat Combined Dyslipidemia of Obesity in Adolescents – The Pediatric Heart Network Dyslipidemia of Obesity Intervention in Teens (DO IT!) Trial

De Ferranti Sarah, Cartoski Mark, Brothers Julie, San Giovanni Christine, Zachariah Justin, Pena Sandra, Mahle William, Peterson Amy, Magge Sheela, Raghuveer Geetha, Sharma Binu, Arslanian, Md Silva, Kazlova Valiantsina, Sponseller Craig, Freemon Dandrea, Stylianou Mario, Mccrindle Brian, Mietus-snyder Michele, Urbina Elaine, Ware Adam, Teng Jessica, Trachtenberg Felicia, Russell Mark, Shah Amy

More abstracts from these authors:
Overcoming the Hurdles: Address CV Risk and Weight in Appropriate Patients

Budoff Matthew

Statin Intolerance due to Muscle Symptoms Affects Management of Patients: Insights from the CLEAR Outcomes Trial

Laufs Ulrich, Lincoff Abraham, Nicholls Stephen, Li Na, Sasiela William, Bloedon Leanne, Robinson Paula, Nissen Steven, Thompson Paul

You have to be authorized to contact abstract author. Please, Login
Not Available